Thales Named as a Market Leader in KuppingerCole Analysts Leadership Compass for Enterprise Authentication
9.3.2021 18:28:00 EET | Business Wire | Press release
Thales today announced that it has been named as a Market Leader in the 2021 KuppingerCole Leadership Compass for Enterprise Authentication.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005761/en/
Copyright Thales
The report recognised Thales as a global leader within the enterprise authentication market through its SafeNet Trusted Access offer. Thales’ primary access management capability received accolades for its authentication support, authorisation and policy management, in addition to strong reporting capabilities, modern user interfaces (UIs) and dashboards. SafeNet Trusted Access supports public cloud and a hybrid deployment model delivered by Managed Service Providers. KuppingerCole evaluated Thales’ standing, following a detailed analysis of other industry players, market reach and analysis of product capabilities.
“Thales’ core enterprise authentication capabilities include good support for basic hardware tokens and popular mobile and cloud app authentication methods. Customers are typically drawn by the high-security options SafeNet provides. Organisations, in both the public and private sectors that need high strength MFA options may want to consider Thales’ SafeNet Suite,” said John Tolbert, Lead Analyst at KuppingerCole.
With more organisations storing data on the cloud than ever before, access management ensures businesses can mitigate the threat of data breaches and simplify cloud access. According to Thales’ 2020 Access Management Index – Europe and Middle East Edition 1, over half (57%) of IT decision makers in Europe and the Middle East identified unprotected infrastructure, such as IoT devices, as the biggest target for cyber-attacks, while nine in 10 (96%) believe that strong authentication and access management solutions can facilitate secure cloud adoption.
“Over the past year, we have witnessed a vast migration to cloud technology as these services become increasingly essential in the current climate with more people working remotely than ever before. However, this move of embracing the cloud for mission-critical applications and IT infrastructure brings increased risk for businesses,” said François Lasnier, Vice President for Access Management solutions at Thales. “As result, we are extremely pleased to have been identified by KuppingerCole as a leader in authentication and access management through SafeNet Trusted Access. This demonstrates Thales’ continued strength, reach and commitment to address customers’ security, compliance and end users’ needs in this new digital-first world.”
SafeNet Trusted Access is a cloud-based access management solution that combines the convenience of single sign-on (SSO) with granular access security controls and adaptive authentication. Through validating identities, enforcing access policies and applying Smart SSO, SafeNet Trusted Access helps companies to meet compliance needs, secure convenient access to cloud applications and prevent data breaches.
Download the full KuppingerCole Report Leadership Compass for Access Management.
Industry insight and views on the latest data security trends can be found on the Thales blog. Follow Thales on Twitter, LinkedIn, Facebook and YouTube .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
---
1 The 2020 Access Management Index, is a survey of 400 executives in 7 countries in Europe and the Middle East with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne, commissioned by Thales.
PLEASE VISIT
Thales Group
Security
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005761/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
